Description

PT-141, also known as Bremelanotide, is a synthetic melanocortin peptide examined in laboratory research for its interaction with central melanocortin receptors rather than peripheral vascular pathways.

Research interest focuses on PT-141’s role in neurobehavioral signaling, motivation-related pathways, and hypothalamic response mechanisms. Unlike compounds targeting blood flow or endocrine output, PT-141 is studied for direct neural receptor engagement.

This peptide is frequently included in receptor-binding studies, signal-response mapping, and CNS pathway exploration under controlled research conditions.

OxygenLab’s PT-141 is produced in the United States and formulated to maintain receptor specificity and molecular stability for reliable experimental outcomes.